MH84 improves mitochondrial dysfunction in a mouse model of early Alzheimer’s disease

MH84 improves mitochondrial dysfunction in a mouse model of early Alzheimer’s disease

Abstract Background Current approved drugs for Alzheimer’s disease (AD) only attenuate symptoms, but do not cure the disease. The pirinixic acid derivate MH84 has been characterized as a dual gamma-secretase/proliferator activated receptor gamma (PPARγ) modulator in vitro. Pharmacokinetic studies in...

Full description

Bibliographic Details
Main Authors: Maximilian Pohland, Maren Pellowska, Heike Asseburg, Stephanie Hagl, Martina Reutzel, Aljoscha Joppe, Dirk Berressem, Schamim H. Eckert, Mario Wurglics, Manfred Schubert‐Zsilavecz, Gunter P. Eckert
Format: Article
Language:English
Published: BMC 2018-02-01
Series:Alzheimer’s Research & Therapy
Subjects:
Alzheimer’s disease
Mitochondrial dysfunction
PPAR gamma activator
PGC-1 alpha
APP processing
Amyloid-beta
Online Access:http://link.springer.com/article/10.1186/s13195-018-0342-6

Internet

http://link.springer.com/article/10.1186/s13195-018-0342-6

Similar Items